1. Home
  2. GERN vs GHLD Comparison

GERN vs GHLD Comparison

Compare GERN & GHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • GHLD
  • Stock Information
  • Founded
  • GERN 1990
  • GHLD 1960
  • Country
  • GERN United States
  • GHLD United States
  • Employees
  • GERN N/A
  • GHLD N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • GHLD Finance: Consumer Services
  • Sector
  • GERN Health Care
  • GHLD Finance
  • Exchange
  • GERN Nasdaq
  • GHLD Nasdaq
  • Market Cap
  • GERN 853.5M
  • GHLD 813.7M
  • IPO Year
  • GERN 1996
  • GHLD 2020
  • Fundamental
  • Price
  • GERN $1.51
  • GHLD $19.76
  • Analyst Decision
  • GERN Buy
  • GHLD Hold
  • Analyst Count
  • GERN 7
  • GHLD 6
  • Target Price
  • GERN $4.17
  • GHLD $16.30
  • AVG Volume (30 Days)
  • GERN 10.9M
  • GHLD 67.2K
  • Earning Date
  • GERN 08-07-2025
  • GHLD 08-07-2025
  • Dividend Yield
  • GERN N/A
  • GHLD 2.53%
  • EPS Growth
  • GERN N/A
  • GHLD 63.18
  • EPS
  • GERN N/A
  • GHLD 0.71
  • Revenue
  • GERN $116,293,000.00
  • GHLD $1,131,796,000.00
  • Revenue This Year
  • GERN $160.12
  • GHLD $5.64
  • Revenue Next Year
  • GERN $55.01
  • GHLD $26.37
  • P/E Ratio
  • GERN N/A
  • GHLD $27.80
  • Revenue Growth
  • GERN 22264.04
  • GHLD 32.57
  • 52 Week Low
  • GERN $1.17
  • GHLD $11.21
  • 52 Week High
  • GERN $5.06
  • GHLD $20.15
  • Technical
  • Relative Strength Index (RSI)
  • GERN 51.36
  • GHLD 82.47
  • Support Level
  • GERN $1.42
  • GHLD $14.69
  • Resistance Level
  • GERN $1.58
  • GHLD $20.15
  • Average True Range (ATR)
  • GERN 0.10
  • GHLD 0.63
  • MACD
  • GERN -0.01
  • GHLD 0.54
  • Stochastic Oscillator
  • GERN 40.00
  • GHLD 94.54

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About GHLD Guild Holdings Company

Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.

Share on Social Networks: